Blinatumomab
B-Cell Childhood Acute Lymphoblastic Leukemia
Seoul National University Hospitalmonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the B-Cell Childhood Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vincristine Sulfate St. Jude Children's Research Hospital | Phase 3 | A |
Pegaspargase St. Jude Children's Research Hospital | Phase 3 | A |
Mercaptopurine Anhydrous St. Jude Children's Research Hospital | Phase 3 | A |
Methotrexate St. Jude Children's Research Hospital | Phase 3 | BBB |
Cytarabine St. Jude Children's Research Hospital | Phase 3 | BBB |
View all 43 →
Same molecule, other indications
Blinatumomab is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Active
BBB
Indicative · Phase 3
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →